SAGE Therapeutics to Present at Canaccord Genuity 34th Annual Growth Conference
SAGE Therapeutics Announces Closing of Initial Public Offering
SAGE Therapeutics Receives Fast Track Designation for Lead Compound SAGE-547 to Treat Status Epilepticus
SAGE Therapeutics is a neuroscience-focused company developing medicines to treat life-threatening, rare CNS disorders. SAGE’s lead program, SAGE-547, is in clinical development for super-refractory status epilepticus (SRSE) and is the first of many compounds the company is developing in its portfolio of potential seizure medicines. SAGE’s robust chemistry platform has generated multiple new compounds that target the GABAA and NMDA receptors, which have demonstrated preclinical activity. SAGE Therapeutics is a public company launched in 2010 by an experienced team of R&D leaders, CNS experts and investors.